Theravance shares surge 20.19% intraday after Q3 earnings beat estimates and price target raised to $20.00.

Theravance Biopharma (TBPH) surged 20.19% intraday following a Q3 earnings report exceeding estimates, with adjusted earnings of 4 cents per share versus a projected loss of 3 cents. Revenues rose 19% year-over-year to $20 million, driven by collaboration income from Viatris under the Yupelri partnership. Analysts at HC Wainwright & Co. raised the price target by 33.33% to $20.00, citing strong financial discipline and the CYPRESS trial for ampreloxetine nearing a Q1 2026 readout, which could unlock $500M+ in value. The company’s $332.7M cash reserves and projected operational breakeven position further bolster investor confidence, aligning with its strategic pivot toward diversified revenue streams and high-impact clinical milestones.